Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Palmoplantar Psoriasis

Interventions: Biological: secukinumab 300 mg
Biological: Placebo
Biological: secukinumab 150 mg

First Posted Date: 2013-03-07

Last Posted Date: 2018-02-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 205

Registration Number: NCT01806597

Locations: 🇬🇧
Novartis Investigative Site, Dudley, West Midlands, United Kingdom

A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: QAW039
Drug: Placebo
Drug: Montelukast

First Posted Date: 2013-03-05

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 188

Registration Number: NCT01804400

Locations: 🇩🇪
Novartis Investigative Site, Hannover, Germany

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Phase 2

Completed

Conditions: Hematologic Neoplasms

Interventions: Drug: Panobinostat

First Posted Date: 2013-03-04

Last Posted Date: 2019-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT01802879

Locations: 🇺🇸
Georgia Regents University SC-2, Augusta, Georgia, United States
🇺🇸
City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1), Duarte, California, United States
🇺🇸
Dana Farber Cancer Institute Reg. Ped, Boston, Massachusetts, United States

and more 2 locations

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Phase 2

Terminated

Conditions: Polymyositis

Interventions: Drug: Placebo
Drug: BAF312

First Posted Date: 2013-03-01

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01801917

Locations: 🇨🇳
Novartis Investigative Site, Taichung, Taiwan

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

Phase 4

Completed

Conditions: COPD

Interventions: Drug: theophylline based treatment
Drug: Other treatment

First Posted Date: 2013-02-20

Last Posted Date: 2019-09-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2229

Registration Number: NCT01794780

Locations: 🇨🇳
Novartis Investigative Site, Zhengzhou, China

Study of FTY720 in Patients With Uveitis

Phase 2

Withdrawn

Conditions: Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Interventions: Drug: FTY720
Drug: Oral Corticosteroid

First Posted Date: 2013-02-13

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01791192

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4

Completed

Conditions: Neoplasms

Interventions: Drug: Everolimus
Drug: Sandostatin LAR Depot

First Posted Date: 2013-02-12

Last Posted Date: 2021-06-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT01789281

Locations: 🇺🇸
New York University Medical Center SC-4, New York, New York, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute SC-2, Tampa, Florida, United States
🇺🇸
Rocky Mountain Cancer Centers SC, Greenwood Village, Colorado, United States

and more 11 locations

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase 1

Completed

Conditions: Blood Platelet Disorders
Hemorrhagic Disorders
Polycythemia Vera
Myeloproliferative Disorders
Bone Marrow Diseases
Primary Myelofibrosis
Essential Thrombocythemia
Thrombocytosis
Hematologic Diseases
Blood Coagulation Disorders

Interventions: Drug: LDE225
Drug: INC424

First Posted Date: 2013-02-08

Last Posted Date: 2020-04-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT01787552

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: LCZ696
Drug: Olmesartan
Drug: Placebo of LCZ696
Drug: Placebo of Olmesartan

First Posted Date: 2013-02-07

Last Posted Date: 2016-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1438

Registration Number: NCT01785472

Locations: 🇹🇭
Novartis Investigative Site, Rajathevee, Thailand

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: QAW039
Drug: Placebo

First Posted Date: 2013-02-07

Last Posted Date: 2015-12-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 103

Registration Number: NCT01785602

Locations: 🇿🇦
Novartis Investigative Site, Durban, South Africa

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy